Publikation
Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland.
Wissenschaftlicher Artikel/Review - 10.06.2022
Brock Elisabeth, Moschovitis Giorgio, Maeder Micha, Pfister Otmar
Bereiche
PubMed
DOI
Kontakt
Zitation
Brock E, Moschovitis G, Maeder M, Pfister O. Budget Impact of Intravenous Iron Therapy with Ferric Carboxymaltose in Patients with Chronic Heart Failure with Reduced Ejection Fraction (HFrEF) and Iron Deficiency in Switzerland. Pharmacoecon Open 2022; 6:735-743.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Pharmacoecon Open 2022; 6
Veröffentlichungsdatum
10.06.2022
eISSN (Online)
2509-4254
Seiten
735-743
Kurzbeschreibung/Zielsetzung
A budget impact analysis compared treating patients with heart failure (HF) and reduced ejection fraction (HFrEF) and iron deficiency (ID) in Switzerland with intravenous ferric carboxymaltose (FCM) or placebo.